IGF-IR and its inhibitors in gastrointestinal carcinomas

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 195-201

  Bao, Xiao Hong ^a   Nomoto, Yoshio ^a   Hao, Hui Fang ^a   Watanabe, Nobuyuki ^a   Sakurama, Kazufumi ^a   Noma, Kazuhiro ^a   Motoki, Takayuki ^a   Tomono, Yasuko ^b   Fukazawa, Takuya ^a   Shirakawa, Yasuhiro ^a   Yamatsuji, Tomoki ^a   Matsuoka, Junji ^a   Takaoka, Munenori ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Okayama   (Japan)

Author keywords

Cancer therapy; Gastrointestinal carcinoma; Monoclonal antibody; Type I insulin like growth factor receptor; Tyrosine kinase inhibitor

Indexed keywords

BVP 51004; CASPASE 3; CETUXIMAB; CISPLATIN; CP 751871; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUINDOSTATIN; FLUOROURACIL; IMC A12; IMMUNOGLOBULIN G1; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MK 0646; NAVELBINE; NORDIHYDROGUAIARETIC ACID; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; PODOPHYLLIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

5' UNTRANSLATED REGION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL MOTILITY; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; ENZYME ACTIVATION; EPITHELIUM CELL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEASIBILITY STUDY; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNAL RIBOSOME ENTRY SITE; LARREA DIVARICATTA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE MYELOMA; NEPHROBLASTOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOGENESIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECTUM CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SHRUB; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSLATION REGULATION;

EID: 77955753972     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000036     Document Type: Review

References (66)

1. Ryan PD and Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13: 16-24, 2008.
2. Miller BS and Yee D: Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65: 10123-10127, 2005.
3. Baserga R: Oncogenes and the strategy of growth factors. Cell 79: 927-930, 1994.
4. Adachi Y, Yamamoto H, Imsumran A, et al: Insulin-like growth factor-I receptor as a candidate for a novel molecular target in the gastrointestinal cancers. Dig Endosc 18: 245-251, 2006.
5. Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 3: 298-302, 2002.
6. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
7. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ER K, JNK and p38 protein kinases. Science 298: 1911-1912, 2002.
8. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95: 2086-2095, 2002.
9. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 21: 755-764, 2004.
10. Imsumran A, Adachi Y, Yamamoto H, et al: Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28: 947-956, 2007.
11. Bergmann U, Funatomi H, Yokoyama M, Beger HG and Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55: 2007-2011, 1995.
12. Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM and Li XS: Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 12: 3977-3982, 2006.
13. Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine 28: 20-47, 2007.
14. Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370, 2008.
15. Kwon J, Stephan S, Mukhopadhyay A, Muders MH, Dutta SK, Lau JS and Mukhopadhyay D: Insulin receptor substrate-2- mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. Cancer Res 69: 1350-1357, 2009.
16. Almeida A, Muleris M, Dutrillaux B and Malfoy B: The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer 11: 63-65, 1994.
17. Berns EM, Klijn JG, van Staveren IL, Portengen H and Foekens JA: Sporadic amplifi cation of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52: 1036-1039, 1992.
18. Armengol G, Knuutila S, Lluís F, Capellà G, Miró R and Caballín MR: DNA copy number changes and evaluation of MYC, IGF1R and FES amplifi cation in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet 116: 133-141, 2000.
19. Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K and Jones C: Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. Cancer Res 66: 11148-11155, 2006.
20. Meng Z, Jackson NL, Choi H, King PH, Emanuel PD and Blume SW: Alterations in RN A-binding activities of IRES -regulatory proteins as a mechanism for physiological variability and pathological dys-regulation of IGF-IR translational control in human breast tumor cells. J Cell Physiol 217: 172-183, 2008.
21. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G and Kaaks R: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917, 2000.
22. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E and Kaaks R: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3 and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50: 642-646, 2002.
23. Nakamura M, Miyamoto S, Maeda H, Zhang SC, Sangai T, Ishii G G, Hasebe T, Endoh Y, Saito N, Asaka M and Ochiai A: Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers. Clin Cancer Res 10: 8434-8441, 2004.
24. Höpfner M, Baradari V, Huether A, Schöfl C and Scherübl H: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135-149, 2006.
25. Hopfner M, Sutter AP, Huether A, Baradari V and Scherubl H: Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 12: 5635-5643, 2006.
26. Piao W, Wang Y, Adachi Y, et al: Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 7: 1483-1493, 2008.
27. Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE and Ellis LM: Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5: 1676-1682, 2006.
28. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis LM: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth and metastasis of colon cancer. Lab Invest 82: 1377-1389, 2002.
29. Gooch JL, van Den Berg CL and Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10, 1999.
30. Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y and Beech DJ: Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94: 1-5, 2000.
31. Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP and Imai K: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54: 591-600, 2005.
32. Ullrich A, Gray A, Tam AW, et al: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that defi ne functional specifi city. EMBO J 5: 2503-2512, 1986.
33. Hofmann F and Garcia-Echeverria C: Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10: 1041-1047, 2005.
34. Lee JS, Weiss J, Martin JL and Scott CD: Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 107: 564-570, 2003.
35. Zhang X and Yee D: Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 62: 4369-4375, 2002.
36. Goya M, Miyamoto S, Nagai K, et al: Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64: 6252-6258, 2004.
37. Pollak M: Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-638, 2008.
38. Rodon J, DeSantos V, Ferry RJ Jr and Kurzrock R: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588, 2008.
39. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P and Gualberto A: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26: 3196-3203, 2008.
40. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S and Gualberto A: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 27: 2516-2522, 2009.
41. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS and Moyer JD: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073. 2005.
42. Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921, 2003.
43. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ and Harari PM: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67: 1155-1162, 2007.
44. Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56: 343-357, 2007.
45. Prewett M, Damoci C, Bassi R, Ludwig DL, Hicklin DJ and Tonra JR: IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts. Proc Am Assoc Cancer Res 48: 652, 2007.
46. ® combined with antibodies targeting IGF1R or VEG FR-2. Proc Am Assoc Cancer Res 46: 1193, 2005.
47. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF and Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the anti-tumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316-328, 2005.
48. Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Corvaïa N and Goetsch L: Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer 124: 2281-2293, 2009.
49. Pandini G, Wurch T, Akla B, et al: Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43: 1318-1327, 2007.
50. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J and Goldfine ID: Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 94: 37-46, 2005.
51. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF and Goldfine ID: Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 103: 624-635, 2008.
52. Rowe DL, Ozbay T, Bender LM and Nahta R: Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther 7: 1900-1908, 2008.
53. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ and Youngren JF: A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 101: 436-439, 2008.
54. Garcia-Echeverria C, Pearson MA, Marti A, et al: In vivo antitumor activity of NVP-AEW541 - a novel, potent and selective inhibitor of the IGF-IRkinase. Cancer Cell 53: 231-239, 2004.
55. Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK and Stoeltzing O: Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 44: 1577-1586, 2008.
56. Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D and Scherübl H: Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Bio Chem Pharmacol 71: 1435-1448, 2006.
57. Kaulfuss S, Burfeind P, Gaedcke J and Scharf JG: Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 8: 821-833, 2009.
58. Favelyukis S, Till JH, Hubbard SR and Miller WT: Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8: 1058-1063, 2001.
59. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242, 2004.
60. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M and Larsson O: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23: 7854-7862, 2004.
61. Menu E, Jernberg-Wiklund H, Stromberg T, de Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, van Camp B and Vanderkerken K: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655-660, 2006.
62. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P and Breuhahn K: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48: 146-156, 2008.
63. Menu E, Jernberg-Wiklund H, de Raeve H, et al: Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121: 1857-1861, 2007.
64. Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L and Larsson O: Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 27: 1629-1638, 2008.
65. Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M and Girnita L: Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol 73: 930-939, 2008.
66. Linder S, Shoshan MC and Gupta RS: Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor. Cancer Res 67: 2899-2900, 2007.